ArticleBMC cancer2007
Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells.
Article in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 85 citations in OpenAlex.
- Bioinformatic Approach to Identify PotentialInternational journal of molecular sciences · 2025Article
- CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Safety of Gonadal Tissue-Derived Mesenchymal Stem Cell Therapy in Geriatric Dogs with Chronic Disease.Animals : an open access journal from MDPI · 2024Article
- CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.BMC cancer · 2024Article
- Advancement of fluorescent aminopeptidase probes for rapid cancer detection-current uses and neurosurgical applications.Frontiers in surgery · 2024Review
- Therapeutic Performance Evaluation ofPharmaceutics · 2023Article
- Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway.Disease markers · 2022Article
- Near-Infrared Fluorescent Probes for the Detection of Cancer-Associated Proteases.ACS chemical biology · 2021Review
- Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization.Cell death & disease · 2021Article
- Synthesis and evaluation ofJournal of Cancer · 2021Article
- An APN-activated NIR photosensitizer for cancer photodynamic therapy and fluorescence imaging.Biomaterials · 2020Article
- Article
- Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma.Disease markers · 2017Article
- Preclinical activity of melflufen (J1) in ovarian cancer.Oncotarget · 2016Article
- A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.International journal of oncology · 2016Article
- The Aminopeptidase CD13 Induces Homotypic Aggregation in Neutrophils and Impairs Collagen Invasion.PloS one · 2016Article
- Putative mesenchymal stem cells isolated from adult human ovaries.Journal of assisted reproduction and genetics · 2014Article
- Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.British journal of cancer · 2013Article
- Peptide targeting of adenoviral vectors to augment tumor gene transfer.Cancer gene therapy · 2012Article
- Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAminopeptidase N (APN/CD13), a 150-kDa metalloprotease, is a multifunctional cell surface aminopeptidase with ubiquitous expression. Recent studies have suggested that APN/CD13 plays an important role in tumor progression of several human malignancies. In the current study, we investigated the role of APN/CD13 in ovarian carcinoma (OVCA) progression.
methodsWe first examined the expression of APN/CD13 at the protein level in a variety of OVCA cell lines and tissues. We subsequently investigated whether there was a correlation between APN/CD13 expression and invasive potential of various OVCA cell lines. Moreover, we investigated the function of APN/CD13 in OVCA cells using bestatin, an APN/CD13 inhibitor, or transfection of siRNA for APN/CD13.
resultsWe confirmed that APN/CD13 was expressed in OVCA tissues and cell lines to various extents. There was a positive correlation between APN/CD13 expression and migratory potential in various OVCA cell lines with accordingly enhanced secretion of endogenous MMP-2. Subsequently, we found a significant decrease in the proliferative and migratory abilities of OVCA cells after the addition of bestatin or the inhibition of APN/CD13 expression by siRNA. Furthermore, in an animal model, daily intraperitoneal administration of bestatin after inoculation of OVCA cells resulted in a decrease of peritoneal dissemination and in prolonged survival of nude mice.
conclusionThe current data indicate the possible involvement of APN/CD13 in the development of OVCA, and suggest that clinical use of bestatin may contribute to better prognosis for ovarian carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.